UY23327A1 - Proceso para la preparacion de muteina humana del factor de necrosis tumoral - Google Patents

Proceso para la preparacion de muteina humana del factor de necrosis tumoral

Info

Publication number
UY23327A1
UY23327A1 UY23327A UY23327A UY23327A1 UY 23327 A1 UY23327 A1 UY 23327A1 UY 23327 A UY23327 A UY 23327A UY 23327 A UY23327 A UY 23327A UY 23327 A1 UY23327 A1 UY 23327A1
Authority
UY
Uruguay
Prior art keywords
necrosis factor
tumor necrosis
human
mutein
preparation
Prior art date
Application number
UY23327A
Other languages
English (en)
Inventor
Walter Fiers
Jan Tavernier
Ostade Xaveer Van
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY23327A1 publication Critical patent/UY23327A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Es objeto de la presente invención el proporcionar una muteína del factor de necrosis tumoral humano o una sal farmacéutica aceptable de la misma, caracterizada porque la secuencia de TNF está cambiada por delección, inserción y/o sustitución de uno o mas aminoácidos de forma que la muteína presenta una diferencia significativa entre su afinidad para la unión con el receptor del factor de necrosis tumoral p75 humano y el receptor del factor de necrosis tumoral p55 humano, secuencias de ADN que codifican dichas muteínas, vectores que comprenden dichas secuencias de ADN, células hospedadoras transformadas con dichos vectores y un procedimiento para la producción de dichas muteínas.
UY23327A 1990-11-21 1991-11-19 Proceso para la preparacion de muteina humana del factor de necrosis tumoral UY23327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90810901 1990-11-21

Publications (1)

Publication Number Publication Date
UY23327A1 true UY23327A1 (es) 1992-05-19

Family

ID=8205969

Family Applications (1)

Application Number Title Priority Date Filing Date
UY23327A UY23327A1 (es) 1990-11-21 1991-11-19 Proceso para la preparacion de muteina humana del factor de necrosis tumoral

Country Status (17)

Country Link
US (2) US5422104A (es)
EP (1) EP0486908A3 (es)
JP (1) JPH06256395A (es)
AR (1) AR245783A1 (es)
AU (1) AU655948B2 (es)
CA (1) CA2055168A1 (es)
FI (1) FI915379A (es)
HU (1) HUT62034A (es)
IE (1) IE914035A1 (es)
IL (1) IL100062A0 (es)
MC (1) MC2300A1 (es)
MX (1) MX9102110A (es)
NO (1) NO914541L (es)
NZ (1) NZ240595A (es)
PT (1) PT99560A (es)
UY (1) UY23327A1 (es)
ZA (1) ZA919035B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK376492A3 (en) * 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP1069917A4 (en) * 1998-03-20 2005-02-09 Genzyme Corp NEW COMPLEMENTARY PAIRS OF RECEPTORS / LIGANDS AND ADOPTIVE IMMUNOTHERAPY USING THE SAME
ATE329610T1 (de) * 2000-02-16 2006-07-15 Genentech Inc Anti-april antikörper und hybridomazellen
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US20050070689A1 (en) * 2001-08-03 2005-03-31 Genentech, Inc. Taci and br3 polypeptides and uses thereof
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
WO2004011611A2 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
CA2526402A1 (en) * 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP1687032B1 (en) * 2003-11-14 2010-02-24 Genvec, Inc. Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
TW200526780A (en) * 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
EP1598075A1 (en) * 2004-05-21 2005-11-23 LEK Pharmaceuticals d.d. Process for the isolation and / or purification of proteins
GB0425972D0 (en) 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
JP2008526889A (ja) * 2005-01-10 2008-07-24 リサーチ ディベロップメント ファウンデーション 癌治療のための標的化キメラ分子
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2008127515A1 (en) * 2007-03-01 2008-10-23 Cytologic, Inc. Compositions and method for enhancing immune responses in mammals
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
MX2019005242A (es) 2016-11-09 2019-09-10 Philogen Spa Inmunoconjugados mutantes de interleucina-2 y de factor de necrosis tumoral.
AU2021332460A1 (en) 2020-08-27 2023-04-06 Enosi Therapeutics Corporation Methods and compositions to treat autoimmune diseases and cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
GR851626B (es) * 1984-07-05 1985-11-26 Genentech Inc
EP0251037B1 (en) * 1986-06-20 1994-06-15 Dainippon Pharmaceutical Co., Ltd. Novel human TNF polypeptide mutants and DNAs encoding said mutants
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
JPS63291590A (ja) * 1987-05-25 1988-11-29 Teijin Ltd 新規生理活性ポリペプチド
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide

Also Published As

Publication number Publication date
IE914035A1 (en) 1992-06-03
EP0486908A3 (en) 1992-11-19
AU655948B2 (en) 1995-01-19
HU913595D0 (en) 1992-01-28
US5422104A (en) 1995-06-06
IL100062A0 (en) 1992-08-18
JPH06256395A (ja) 1994-09-13
FI915379A (fi) 1992-05-22
CA2055168A1 (en) 1992-05-22
ZA919035B (en) 1992-08-26
NZ240595A (en) 1994-09-27
AU8791591A (en) 1992-05-28
NO914541L (no) 1992-05-22
US5652353A (en) 1997-07-29
HUT62034A (en) 1993-03-29
AR245783A1 (es) 1994-02-28
EP0486908A2 (en) 1992-05-27
MX9102110A (es) 1992-07-08
MC2300A1 (fr) 1993-09-06
NO914541D0 (no) 1991-11-20
PT99560A (pt) 1992-10-30
FI915379A0 (fi) 1991-11-14

Similar Documents

Publication Publication Date Title
UY23327A1 (es) Proceso para la preparacion de muteina humana del factor de necrosis tumoral
MY101887A (en) A novel human physiologically active polypeptide.
BG64881B2 (en) TNF-BINDING PROTEINS
MX9301700A (es) Muteinas del factor de necrosis tumoral humano, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
SG47766A1 (en) CD2-binding domain of lymphocyte function associated antigen 3
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
DE69738370D1 (de) Modulatoren des tnf-rezeptor-assoziierten faktors, deren herstellung und verwendungen
Goth et al. Aspartic acid 50 and tyrosine 108 are essential for receptor binding and cytotoxic activity of tumour necrosis factor beta (lymphotoxin)
IT1247165B (it) Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie.
NO20011460L (no) Cytokinreseptor zalphall
MX9203138A (es) Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
YU199691A (sh) Receptor za humani interleukin-5
EP0369816A3 (en) Monoclonal antibodies specific for human polymorphic epithelial mucin
ATE508194T1 (de) Neue cytokinine aus vögeln und dafür codierende genetische sequenzen
NO983238L (no) Exodus kjemokin materialer og fremgangsmÕter
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
DK0421949T3 (da) Kemisk modificerede allergener og fremgangsmåde til deres fremstilling
NZ505827A (en) Concatamers of non-identical genes for the same polypeptide and their application in vaccines
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
DE68905097D1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
YU182791A (sh) Tnf-muteini
Palladino Jr et al. Immunopharmacology of tumor necrosis factors α and β
DK0540560T3 (da) Ancrod-lignende proteiner, fremstilling og anvendelse deraf
BR0012740A (pt) Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20110123